Immune Memory Could Be Behind Recurring Arthritis While Patients Undergo Cancer Immunotherapy

immunotherapy against cancer. In many of these cases, the inflammation recurs, and the treatment impacts the quality of life of the affected patients. Scientists have been trying to understand why this type of adverse event happens, and a new study sheds some light on the issue. 

The study, whose findings appeared in the journal Cancer Immunology Research, was conducted by a team at the Yale School of Medicine. Their work points to a possible role of immune memory in triggering stronger flare ups of inflammation in the joints of patients. 

For their study, the team obtained joint fluid from cancer patients during the first flare up of arthritis as those patients underwent immunotherapy, and also during a subsequent occurrence of arthritis. They analyzed the various groups of T-cells responsible for inflammation in those samples, and they also analyzed the genes that were present in each of those immune system cells. 

Their analysis revealed that the immune cells linked to inflammation were present in larger numbers during the second flare up of arthritis when compared to the numbers found during the first incident. 

This discovery suggests that those immune cells could be responsible for the recurrence of arthritis that patients present with while undergoing immunotherapy to treat the cancers they have been diagnosed with. They explain that this scenario is linked to a natural process within the immune system. 

Under normal circumstances, when the immune system encounters new antigens, such as after a person has been vaccinated, the immune system develops a response to those antigens, and it stores information about those antigens so that when it encounters them another time, it already knows what to do and reacts quickly. This is how vaccination works, by priming the immune system to deal with an infection of, say, measles. 

This could explain why the patients who develop a rheumatological adverse event may tend to have their arthritis recur more strongly when they continue their immunotherapy. 

The second flare up tends to be stronger because the immune system remembers the antigens and can react more strongly when it is next exposed to them. While this can be a good thing in other scenarios, it gets in the way of patients continuing their immunotherapy against cancer, and the researchers want to study the subject further in order to find ways to stop this natural immune response from becoming a problem. 

The study team wants to conduct further studies to find out whether the cells triggering the rheumatological adverse effect also play a part in combating cancer, and if not, how they can manage this reaction so that immunotherapy can proceed without letting the rheumatological reaction get in the way. 

Additionally, the team wants to establish whether these cells triggering the arthritis can also be detected in blood samples. If this is established, blood tests can be incorporated into the ongoing monitoring of patients so that those likely to experience an arthritis recurrence are identified early and proactive steps are taken to forestall the flare up. 

A lot is still being discovered about why immunotherapy works for some patients and not others, and why some patients respond differently while undergoing this treatment. We can therefore expect more insights on this relatively new approach to treating cancer as enterprises like Calidi Biotherapeutics Inc. (NYSE American: CLDI) proceed with their R&D programs. 

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Archives

Select A Month

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000